YUKIGUNI FACTORY CO.,LTD.
1375・Prime Market・Fishery, Agriculture & Forestry
Mushroom Business
Core segment of Yukiguni Factory responsible for manufacturing and selling mushrooms (approx. 99% of consolidated revenue)
| Period | Current | Previous | Change |
|---|---|---|---|
| Mushroom Business Revenue (Full Year) | ¥37,471 million | ¥36,779 million | ↑ |
| Mushroom Business Segment Profit (Full Year) | ¥4,384 million | ¥2,511 million | ↑ |
| Mushroom Business Depreciation and Amortization (Full Year) | ¥2,271 million | ¥2,324 million | ↓ |
| Mushroom Business Impairment Loss (Full Year) | ¥98 million | ¥1,599 million | ↓ |
| Maitake Revenue (Full Year) | ¥20,264 million | ¥20,055 million | ↑ |
| Eryngii Revenue (Full Year) | ¥3,973 million | ¥3,822 million | ↑ |
| Bunashimeji Revenue (Full Year) | ¥7,948 million | ¥7,563 million | ↑ |
| Other Mushrooms Revenue (Full Year) | ¥5,284 million | ¥5,337 million | ↓ |
Business Details
The segment stably manufactures mushroom varieties—including maitake, eryngii, bunashimeji, mushroom, hon-shimeji, and hatake-shimeji—using industrial production methods, with sales centered on direct distribution to retailers. The company promotes a premium strategy centered on its proprietary "Kiwami" brand, supplying high-quality mushroom products to domestic and overseas customers. Overseas, group companies market exotic mushrooms in the European market. The segment applies IAS 41 "Agriculture," measuring biological assets at fair value.
Recent Overview
Segment profit rebounded sharply, up 74.6% year on year, mainly due to a significant reduction in impairment loss
Revenue in the mushroom business for FY2026 (ending March 2026) trended solidly at ¥37,471 million (up 1.9% year on year). Eryngii (+3.9%) and bunashimeji (+5.1%) led the growth, while maitake increased only 1.0% as an increase in sales volume offset a decline in average selling price. Segment profit rose sharply to ¥4,384 million (up 74.6% year on year), mainly due to the impairment loss shrinking to ¥98 million in the current period from ¥1,599 million in the prior period. In November 2025, the company upgraded its function to a Research and Development Division and newly established the Mushroom Research Institute and Mirai Research Institute.
Key Products
Growth Drivers
- Improved average selling prices and expanded shelf share through the premium brand strategy (the "Kiwami" series)
- Increased revenue contribution from improvements in both sales volume and average selling price for eryngii and bunashimeji
- Expansion of exotic mushroom sales in Europe by overseas group companies (trending favorably)
- Creation of new technologies and products through the upgrade to a Research and Development Division and the establishment of the Mushroom Research Institute/Mirai Research Institute
- Improved production efficiency and labor-saving investment through FA (factory automation) and automation promotion (rationalization of all processes through BPR)
- Expanded sales of the new business product "Kinoko no Niku" (Mushroom Meat) series (sales launched in February 2025)
- Acquisition of a new user base through continuous promotion utilizing social media and digital media
Risks
- Cost pressure from persistently elevated raw material costs, labor costs, logistics costs, and packaging material costs (further increases in material costs and labor costs expected in FY2027 as well)
- Downward pressure on maitake average selling prices due to continued consumer thrift and selective spending
- Uncertainty in profit or loss arising from fair value changes in biological assets under IAS 41 application (affected by fluctuations in production volume, sales volume, selling prices, etc.)
- Risk of impairment losses (declined from ¥1,599 million in the prior period to ¥98 million in the current period, but underlying risk persists given the large amount of fixed assets)
- Shrinking trend in the domestic food market due to the declining birthrate, aging population, and population decline
- Impact of exchange rate fluctuations on raw material procurement costs and overseas business profit or loss
- Uncertainty in the external environment due to geopolitical risks such as escalating tensions in the Middle East and US trade policy developments
- Difficulty securing labor due to a shrinking domestic labor population and rising personnel costs
Other
New and peripheral business segment encompassing health foods, alternative meat, culture medium activators, and other businesses outside the mushroom business
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue (Full Year FY2026, ending March 2026) | ¥373 million | ¥322 million | ↑ |
| Revenue YoY Change Rate (Full Year FY2026, ending March 2026) | up 15.9% | - | ↑ |
| Segment Operating Profit (Full Year FY2026, ending March 2026) | -¥98 million | -¥77 million | ↓ |
| Depreciation and Amortization (Full Year FY2026, ending March 2026) | ¥20 million | ¥23 million | ↓ |
| Share of Group Revenue (Full Year FY2026, ending March 2026) | approx. 1.0% | approx. 0.9% | ↑ |
Business Details
This segment comprises the manufacturing (outsourced) and sale of health foods, the manufacturing (outsourced) and sale of the "Kinoko no Niku" (Mushroom Meat) series of mushroom-based alternative meat products launched for sale in February 2025, operation of direct sales outlets, and sale of culture medium activators. Although small in scale, accounting for approximately 1.0% of overall group revenue (FY2026, ending March 2026), it plays a central role in expanding new business areas under the medium-term management plan. The segment is handled by Yukiguni Factory Co., Ltd. and its related subsidiaries.
Recent Overview
Revenue expanded 15.9% to ¥373 million, but segment loss widened to -¥98 million
For the full year of FY2026 (ending March 2026), sales of health foods and culture medium activators both trended favorably, and the "Kinoko no Niku" series also worked to raise awareness and strengthen sales through active promotional measures, resulting in revenue expanding to ¥373 million (up 15.9% year on year). On the other hand, due to upfront investments and other factors, the segment operating loss widened to -¥98 million (from -¥77 million in the prior period). In the organizational restructuring of November 2025, the "Mirai Research Institute" was newly established, strengthening the research and development framework for functional materials and new technologies.
Key Products
Growth Drivers
- Increased recognition and expanded sales of the "Kinoko no Niku" series (contributed to a 15.9% year-on-year increase in segment revenue for full year FY2026, ending March 2026)
- Favorable trends in health foods and culture medium activators (both products recorded as trending favorably in full year FY2026, ending March 2026)
- Strengthened research and development of functional materials and new technologies through the "Mirai Research Institute," newly established in November 2025
- Continued active investment in new business areas under the niche/premium business expansion policy based on the medium-term management plan
- Expected growth in demand for mushroom-derived functional materials and alternative meat amid rising health consciousness
Risks
- Risk of expanding segment losses as upfront expenses continue for raising awareness and expanding sales of the "Kinoko no Niku" series (segment loss widened to -¥98 million in full year FY2026, ending March 2026, from -¥77 million in the prior period)
- Limited in-house control over manufacturing costs and quality management for new business products, as manufacturing is outsourced
- Risk that continued consumer thrift will suppress demand for value-added products such as alternative meat and health foods
- Risk that reaching the break-even point will take time due to the segment's small overall revenue scale (¥373 million) and fixed cost burden
Last updated: July 17, 2026

